The EIB invests €85 million for research in the field of chronical diseases treatmentSeptember 7, 2018
Hat: The EIB invests €85 million for research in the field of chronical diseases treatment
Funding Scheme: 2018-09-07
Pgm2014 2020: Yes
The Juncker Plan supports a €85 million loan from the European Investment Bank (EIB) to the pharmaceutical company Grifols to support their research and development activities.
The pharmaceutical company Grifols, established in Barcelona, conduct research, development and innovation activities. These activities aim at developing new treatments to cure chronical and rare diseases.
The company has obtained a €85 million loan contract, signed with the European Investment Bank, in order to support its activities. This loan is supported by the European Fund for Strategic Investment (EFSI), also known as the Juncker Plan.
Since 2015, it is the third time that Grifols benefits from support by the Juncker Plan within the framework of its research, development and innovation activities.
Url description: Press room - European Commission
Url info description: The EIB invests €85 million for research in the field of chronical diseases treatment